Clusterin
CLUproteinClusterin modulates left-ventricular remodeling and angiogenesis following myocardial injury.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleAngiogenic factor regulating post-MI cardiac remodeling and heart-failure progression.
Also acts inLipid entry/oxidation, Myocardial injury
Druggability
DruggableYes
Known drugs / candidates2
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000120885
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I43
C — confounder / Type-II69
A — assay feasibility72
E — evidence strength26
T1DI (composite)7
Specificity differential (R−C)-26
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(3)
- Neonatal Plasma Exosomes Contribute to Endothelial Cell-Mediated Angiogenesis and Cardiac Repair after Acute Myocardial Infarction.International journal of molecular sciences · 2023 · PMID 36834610 · doi
- Expression and Implication of Clusterin in Left Ventricular Remodeling After Myocardial Infarction.Circulation. Heart failure · 2018 · PMID 29891738 · doi
- Proteomic signature of Apolipoprotein J in the early phase of new-onset myocardial infarction.Journal of proteome research · 2010 · PMID 21043527 · doi